Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 5
2011 4
2012 3
2014 3
2015 3
2016 6
2017 9
2018 14
2019 11
2020 9
2021 12
2022 15
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
B cells are associated with survival and immunotherapy response in sarcoma.
Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautès-Fridman C, Tawbi HA, Fridman WH. Petitprez F, et al. Among authors: toulmonde m. Nature. 2020 Jan;577(7791):556-560. doi: 10.1038/s41586-019-1906-8. Epub 2020 Jan 15. Nature. 2020. PMID: 31942077 Free article.
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: toulmonde m. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, Guegan JP, Rey C, Sautès-Fridman C, Bougoüin A, Cantarel C, Kind M, Spalato M, Dadone-Montaudie B, Le Loarer F, Blay JY, Fridman WH. Italiano A, et al. Among authors: toulmonde m. Nat Med. 2022 Jun;28(6):1199-1206. doi: 10.1038/s41591-022-01821-3. Epub 2022 May 26. Nat Med. 2022. PMID: 35618839 Clinical Trial.
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Italiano A, et al. Among authors: toulmonde m. Lancet Oncol. 2020 Mar;21(3):446-455. doi: 10.1016/S1470-2045(19)30825-3. Epub 2020 Feb 17. Lancet Oncol. 2020. PMID: 32078813 Free PMC article. Clinical Trial.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Among authors: toulmonde m. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value.
Penel N, Bonvalot S, Le Deley MC, Italiano A, Tlemsani C, Pannier D, Leguillette C, Kurtz JE, Toulmonde M, Thery J, Orbach D, Dubray-Longeras P, Verret B, Bertucci F, Guillemet C, Laroche L, Dufresne A, Blay JY, Le Cesne A. Penel N, et al. Among authors: toulmonde m. Int J Cancer. 2023 Jul 15;153(2):407-416. doi: 10.1002/ijc.34493. Epub 2023 Mar 25. Int J Cancer. 2023. PMID: 36883417
Insulin amyloidosis: A case report.
Dubernet A, Toulmonde M, Colombat M, Hartog C, Riviere E. Dubernet A, et al. Among authors: toulmonde m. Front Med (Lausanne). 2023 Apr 6;10:1064832. doi: 10.3389/fmed.2023.1064832. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37089584 Free PMC article.
A review of PARP inhibitors: from bench to bedside.
Underhill C, Toulmonde M, Bonnefoi H. Underhill C, et al. Among authors: toulmonde m. Ann Oncol. 2011 Feb;22(2):268-79. doi: 10.1093/annonc/mdq322. Epub 2010 Jul 19. Ann Oncol. 2011. PMID: 20643861 Free article. Review.
Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.
Bompas E, Campion L, Italiano A, Le Cesne A, Chevreau C, Isambert N, Toulmonde M, Mir O, Ray-Coquard I, Piperno-Neumann S, Saada-Bouzid E, Rios M, Kurtz JE, Delcambre C, Dubray-Longeras P, Duffaud F, Karanian M, Le Loarer F, Soulié P, Penel N, Blay JY. Bompas E, et al. Among authors: toulmonde m. Cancer Med. 2018 Aug;7(8):4023-4035. doi: 10.1002/cam4.1374. Epub 2018 Jun 28. Cancer Med. 2018. PMID: 29956493 Free PMC article. Review.
104 results